US-based biopharmaceutical firm TG Therapeutics has commenced enrolment for the Phase III ULTIMATE clinical programme of TG-1101 (ublituximab) to treat patients with relapsing multiple sclerosis (RMS).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

TG-1101 is a glycoengineered monoclonal antibody being developed to target a specific epitope on the CD20 antigen present on mature B-lymphocytes.

The programme comprises global, randomised, multi-centre, double-blinded, double-dummy, active-controlled ULTIMATE I and ULTIMATE II trials that will compare the safety and efficacy of TG-1101 with teriflunomide.

TG Therapeutics executive chairman and CEO Michael Weiss said: "We believe B-cell targeted therapy has the potential to become the leading treatment option for MS and that TG-1101 has the potential to differentiate itself amongst the other B-cell targeted therapies by offering a rapid, convenient one-hour infusion at an attractive price. 

See Also:

"We are highly encouraged by the early data seen in our Phase II trial and look forward to presenting additional data from that study at the ECTRIMS-ACTRIMS meeting next month."

“We are highly encouraged by the early data seen in our Phase II trial and look forward to presenting additional data from that study at the ECTRIMS-ACTRIMS meeting next month."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The programme will be led by Stanford University professor Dr Lawrence Steinman, and enrol a total of 880 subjects, with 440 in each trial.

Dr Steinman said: “We are excited to lead this Phase III trial and evaluate the unique attributes of ublituximab, which may provide a more convenient and possibly less costly treatment option for our patients.”

The primary endpoint for both trials is annualised relapse rate (ARR) after 96 weeks of treatment. 

Image: Photomicrograph of a demyelinating MS-lesion. Photo: courtesy of Marvin 101.